Carcinoma  >>  Lipotecan (TLC388)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipotecan (TLC388) / Taiwan Liposome Company
NCT01831973: A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

Completed
2
18
RoW
Lipotecan, TLC388
Taiwan Liposome Company
Advanced/Metastasis Renal Cell Carcinoma
03/15
02/17
NCT02267213: Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Terminated
2
29
RoW
Lipotecan, Lipotecan, TLC388
Taiwan Liposome Company
Hepatocellular Carcinoma
07/15
07/15
NCT02457273: Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Completed
2
23
RoW
TLC 388, Lipotecan®,
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Taichung Veterans General Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
Neuroendocrine Carcinomas
04/18
12/18
NCT01425996: A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Terminated
1/2
3
RoW
Lipotecan® (TLC388), Lipotecan (TLC388)
Taiwan Liposome Company
Carcinoma, Hepatocellular
10/14
10/14
NCT03035006: Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Terminated
1/2
1
RoW
Lipotecan, TLC388
Taiwan Liposome Company
HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
10/18
10/18

Download Options